RIBBON-1 Revisited

By Lisa Carey. The randomized Phase III trial, Ribbon-1, was designed to examine whether the benefit of bevacizumab added to chemotherapy in metastatic breast cancer was specific to the taxanes or if the benefit could accrue regardless of the chemotherapy backbone. PFS was improved with the addition of bevacizumab to several cytotoxics, including capecitabine, taxanes, and anthracyclines. OS was not improved. This podcast reviews the salient design, results, and implications of this trial and puts it in context of other bevacizumab trials and controversies.